Safety study of ascending doses of KNX100 in Mental Health
This study is completed in Australia. It is testing ascending doses of KNX100 for Mental Health.
Mental healthDrugFrom 18 Years to No limit
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What the source says
The registry describes this research topic: “Study to Examine the Safety, Tolerability and Pharmacokinetics of ascending doses of KNX100 in healthy volunteers”. This is an interventional study. The registry lists a target sample size of 12. Recruitment status at the registry update of 2025-09-13: completed. Read the original description and eligibility criteria, and confirm the practical details with the study team.
What should you check before joining?
Check the full criteria in the official source. Ask the team to confirm recruitment, locations, visits, risks and participation requirements.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateMarch 24, 2025
Recruitment status
Completed
Enrollment listed in the registry
12
Sponsor
Kinoxis Therapeutics Pty Ltd
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
Australia
Age range
From 18 Years to No limit
Official registry ID
ACTRN12625000020482
Official title
KTX-003: A Phase 1 Study evaluating the Safety, Tolerability and Pharmacokinetics of ascending doses of KNX100 in healthy young and elderly volunteers.
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: ACTRN12625000020482. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
No specific site is confirmed in the available information. Check the official source for locations and remote participation.
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Confirm the location and whether remote participation is possible with the research team.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with mental health. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study. Phase 1 studies usually focus mainly on safety, tolerability, dosage, and side effects. They often involve healthy volunteers, but not always. Some Phase 1 studies include people living with the target condition.
Who might this study be for?
This study may concern people with mental health; age range: From 18 Years to No limit. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Kinoxis Therapeutics Pty Ltd, which appears to be a biotech company. The listed contact or investigator is Tiina Ahveninen. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This study is completed in Australia. It is testing Safety and Pharmacokinetics of a Single Intravenous Infusion of TRP-8803 (Psilocin) for Mental health.
